ClinicalTrials.gg
CompletedNCT01087970Updated May 19, 2014Results posted

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

A Phase 2 interventional study of Pemetrexed and Cetuximab in Head and Neck Neoplasms, sponsored by Eli Lilly and Company. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-19.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pemetrexed in Head and Neck Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Pemetrexed · Head and Neck Neoplasms.

Enrollment
3rd of 13
69 · median 36
Started
2010
with 1 other
Phase 2
8 of 13
1 open now
Registered
9th of 13
by date
Lead sponsor
3 of 13
Eli Lilly and Company

Among the 13 studies testing pemetrexed in Head and Neck Neoplasms, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 2, and was the 9th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

1 of the 13 studies testing pemetrexed in Head and Neck Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pemetrexed in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.

03

Conditions studied

  • Head and Neck Neoplasms

Keywords

  • Pharynx
  • Larynx
  • Nose
  • Parathyroid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic diagnosis of squamous cell head and neck cancer (HNC)

    • Recurrent disease (locally advanced or ) that is not amenable to local therapy, (i) with at least 6 months since completion of systemic therapy (chemotherapy or biological anticancer therapy), and (ii) with no more than 1 prior multimodal therapy (such as concurrent chemoradiation with or without sequential chemotherapy) for locally advanced HNC tumor, and (iii) with no prior systemic therapy (chemotherapy or biological anticancer therapy) for metastatic disease; OR
    • Newly diagnosed distant metastatic disease (Stage IVc)
  • Prior therapies:

    • Radiation therapy must be completed at least 4 weeks before study enrollment. For palliative therapy, prior radiation therapy allowed \<25% of the bone marrow and prior radiation to the whole pelvis is not allowed. Participants must have recovered from the acute toxic effects of the treatment prior to study enrollment.
    • Surgery (excluding prior diagnostic ) must be completed at least 4 weeks before study enrollment. Participants must have fully recovered from any acute effects of surgery prior to study enrollment.
  • An estimated of at least 12 weeks.
  • (ECOG) performance status 0 or 1.
  • Biological tissue available for biomarker analysis on tumor tissue.
  • Disease status must be measurable as defined by (RECIST). The index lesion must not be in a prior irradiated area. Positron emission tomography (PET) scans and ultrasounds may not be used for lesion measurements.
  • Participant compliance and geographic proximity that allow for adequate follow-up.
  • Adequate organ function as defined by the following:

    • Bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) greater than or equal to 1.5 × 10⁹/liter (L), greater than or equal to 100 × 10⁹/L, and greater than or equal to 9 grams/deciliter (g/dL).
    • Hepatic: less than or equal to 1.5 × the (ULN); alkaline phosphatase (ALP), (AST), and alanine aminotransferase (ALT) less than or equal to 3.0 × ULN (ALP, AST, and ALT less than or equal to 5.0 × ULN is acceptable if the liver has tumor involvement).
    • Renal: calculated (CrCl) greater than or equal to 45 milliliters/minute (mL/min).
  • For women: Must be surgically sterile, , or compliant with a medically approved regimen during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment, and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period.

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
  • Are receiving concurrent chronic systemic immune therapy, or chemotherapy for a disease other than cancer.
  • Concurrent administration of any other antitumor therapy.
  • Known prior allergic/ reaction to any of the components of the study treatment.
  • Serious concomitant systemic disorder (for example, active infection) or psychiatric disorder that, in the opinion of the investigator, would compromise the participant's ability to complete the study.
  • Have serious cardiac disease, such as symptomatic angina, unstable angina, or the history of myocardial infarction in the previous 12 months.
  • Second primary that is clinically detectable at the time of consideration for study enrollment.
  • Have had another primary malignancy other than HNC, unless that prior malignancy was treated at least 2 years previously with no evidence of recurrence. Exception: Participants with a history of in situ carcinoma of the cervix, nonmelanoma skin cancer, or low-grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed and treated less than 2 years previously.
  • Nasopharyngeal, paranasal sinus, lip, or salivary gland cancer.
  • Presence of (by physical exam) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
  • Have peripheral neuropathy of (CTCAE) Grade 1 or higher.
  • Have central nervous system (CNS) (unless the participant has completed successful local therapy for and has been off for at least 4 weeks before starting study therapy). Brain imaging is required in symptomatic participants to rule out brain metastases, but is not required in asymptomatic participants.
  • Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).
  • Unable or unwilling to take folic acid, vitamin B12, or prophylactic corticosteroids.
  • Recent (within 30 days before enrollment) or concurrent yellow fever vaccination.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Triplet Combination Therapy

    Cycle 1: Week 1 - Cetuximab 400 milligrams/square meter (mg/m²) on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin area under curve (AUC) 5 on Day 1 or Cisplatin 75 mg/m² on Day 1 Week 2 - Cetuximab 250 mg/m² on Day 1 Week 3 - Cetuximab 250 mg/m² on Day 1 Cycle 2-6: Week 1 - Cetuximab 250 mg/m² on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin AUC 5 on Day 1 or Cisplatin 75 mg/m² on Day 1 Week 2 - Cetuximab 250 mg/m² on Day 1 Week 3 - Cetuximab 250 mg/m² on Day 1 Following Cycle 6, Cetuximab Monotherapy: 250 mg/m² intravenously weekly on Day 1

    Drug: Pemetrexed · Drug: Cetuximab · Drug: Carboplatin · Drug: Cisplatin

Interventions

  • Administered intravenously, for maximum of 6 cycles.

    Also known as: Alimta, LY231514

  • Administered intravenously in combination therapy, for a maximum of 6 cycles. After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression.

    Also known as: Erbitux

  • Administered intravenously, for a maximum of 6 cycles

  • Administered intravenously, for a maximum of 6 cycles

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the duration from the date of enrollment to the first date of documented objective progressive disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants who were not known to have died or to have had objective PD at the time of the data inclusion cutoff, PFS was censored at their last objective progression-free disease assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy.

    Time frame: From enrollment to measured progressive disease up to 15.3 months (tumor assessments performed every other cycle during study treatment, and then every 6 weeks during follow-up)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the duration from the date of enrollment to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the date of last contact prior to that cut-off date.

    Time frame: From enrollment to the date of death from any cause up to 26.4 months (assessment completed during trial period at least every 3 months)

  2. Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)

    PR or CR is classified by the investigators according to RECIST criteria version 1.0. PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions; CR is the disappearance of all target and non-target lesions. Percentage of participants having a PR or CR is calculated as a total number of participants with PR or CR from enrollment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.

    Time frame: From enrollment to objectively determined progressive disease up to 15.3 months (tumor assessments performed every other cycle during study treatment until progressive disease)

  3. Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)

    EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state. The EQ-5D Visual Analog Scale (VAS) is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline, Day 1 of Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4 (21-day cycle)

  4. Change From Baseline in Performance Status Scale for Head and Neck Cancer (PSS-HNC)

    PSS-HNC is a clinician-rated instrument designed to measure speaking and eating disabilities of participants with head and neck cancer and consists of 3 subscales: normalcy of diet (NOD) subscale measures the ability of the participants to eat a normal diet, subscale ranges from 0 (non-oral feeding) to 100 (unrestricted diet); understandability of speech (UOS) subscale measures the degree a clinician is able to understand the participant's speech, subscale ranges from 0 (never understandable) to 100 (always understandable); eating in public (EIP) subscale, rating based on the participant's response to the questions of whom he/she eats with and in what setting, subscale ranges from 0 (always eats alone) to 100 (no restriction of place, food, or companion). Change from baseline: negative value represents a decrease in function and a positive value represents an increase in function.

    Time frame: Baseline, Day 1 of Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4 (21-day cycle)

Other outcomes

  1. Number of Participants Who Died While on Treatment and Died During 30-Day Post-Treatment Discontinuation Follow-Up (FU)

    Presented are the number of participants who died due to adverse events (AEs) while on treatment and participants who died due to progressive disease (PD) during the 30-day post-treatment discontinuation FU.

    Time frame: From enrollment to 30 days post-treatment discontinuation up to 26.4 months

07

Results

Posted May 19, 2014
Limitations and caveats
Efficacy populations excluded data from a noncompliant site (11 participants).

Participant flow

Participant flow — Overall Study
MilestoneCetuximab + Pemetrexed + Carboplatin/Cisplatin
Started69
Received ≥1 dose of any study drug69
Completed 6 cycles69
Efficacy population58
Received carboplatin63
Completed67
Not completed2
Withdrew: Protocol violation2

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as the duration from the date of enrollment to the first date of documented objective progressive disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants who were not known to have died or to have had objective PD at the time of the data inclusion cutoff, PFS was censored at their last objective progression-free disease assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy.

Time frame:
From enrollment to measured progressive disease up to 15.3 months (tumor assessments performed every other cycle during study treatment, and then every 6 weeks during follow-up)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsCetuximab + Pemetrexed + Carboplatin/Cisplatin
Progression-Free Survival (PFS)5.1 (3.9 to 6.0)
SecondaryOverall Survival (OS)

OS is defined as the duration from the date of enrollment to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the date of last contact prior to that cut-off date.

Time frame:
From enrollment to the date of death from any cause up to 26.4 months (assessment completed during trial period at least every 3 months)
Reported as:
Median · months
Overall Survival (OS)
monthsCetuximab + Pemetrexed + Carboplatin/Cisplatin
Overall Survival (OS)11.1 (7.6 to 14.8)
SecondaryPercentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)

PR or CR is classified by the investigators according to RECIST criteria version 1.0. PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions; CR is the disappearance of all target and non-target lesions. Percentage of participants having a PR or CR is calculated as a total number of participants with PR or CR from enrollment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.

Time frame:
From enrollment to objectively determined progressive disease up to 15.3 months (tumor assessments performed every other cycle during study treatment until progressive disease)
Reported as:
Number · percentage of participants
Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)
percentage of participantsCetuximab + Pemetrexed + Carboplatin/Cisplatin
Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)25.9 (15.3 to 39.0)
SecondaryChange From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)

EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state. The EQ-5D Visual Analog Scale (VAS) is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline, Day 1 of Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4 (21-day cycle)
Reported as:
Mean · units on a scale
Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)
units on a scaleCetuximab + Pemetrexed + Carboplatin/Cisplatin
Change in Index Score at Cycle 2 (n=43)0.038 ± 0.233
Change in Index Score at Cycle 4 (n=29)0.070 ± 0.147
Change in Index Score at Cycle 6 (n=24)-0.063 ± 0.249
Change in Index Score at monotherapy Cycle2 (n=14)0.016 ± 0.098
Change in Index Score at monotherapy Cycle 4 (n=7)0.059 ± 0.080
Change in VAS Score at Cycle 2 (n=41)3.854 ± 21.600
Change in VAS Score at Cycle 4 (n=28)2.107 ± 24.894
Change in VAS Score at Cycle 6 (n=21)0.333 ± 16.716
Change in VAS Score at monotherapy Cycle 2 (n=14)-1.500 ± 16.919
Change in VAS Score at monotherapy Cycle 4 (n=7)0.571 ± 13.377
SecondaryChange From Baseline in Performance Status Scale for Head and Neck Cancer (PSS-HNC)

PSS-HNC is a clinician-rated instrument designed to measure speaking and eating disabilities of participants with head and neck cancer and consists of 3 subscales: normalcy of diet (NOD) subscale measures the ability of the participants to eat a normal diet, subscale ranges from 0 (non-oral feeding) to 100 (unrestricted diet); understandability of speech (UOS) subscale measures the degree a clinician is able to understand the participant's speech, subscale ranges from 0 (never understandable) to 100 (always understandable); eating in public (EIP) subscale, rating based on the participant's response to the questions of whom he/she eats with and in what setting, subscale ranges from 0 (always eats alone) to 100 (no restriction of place, food, or companion). Change from baseline: negative value represents a decrease in function and a positive value represents an increase in function.

Time frame:
Baseline, Day 1 of Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4 (21-day cycle)
Reported as:
Mean · units on a scale
Change From Baseline in Performance Status Scale for Head and Neck Cancer (PSS-HNC)
units on a scaleCetuximab + Pemetrexed + Carboplatin/Cisplatin
Change in NOD at Cycle 2 (n=52)4.62 ± 18.63
Change in UOS at Cycle 2 (n=52)-2.40 ± 18.69
change in EIP at Cycle 2 (n=52)2.88 ± 21.38
Change in NOD at Cycle 4 (n=34)3.24 ± 24.58
Change in UOS at Cycle 4 (n=35)-0.71 ± 19.63
Change in EIP at Cycle 4 (n=34)-6.62 ± 24.08
Change in NOD at Cycle 6 (n=28)9.29 ± 24.78
Change in UOS at Cycle 6 (n=28)-1.79 ± 16.57
Change in EIP at Cycle 6 (n=28)-1.79 ± 28.81
Change in NOD at monotherapy Cycle 2 (n=16)11.88 ± 32.29
Change in UOS at monotherapy Cycle 2 (n=16)-4.69 ± 16.38
Change in EIP at monotherapy Cycle 2 (n=17)-4.41 ± 35.61
Change in NOD at monotherapy Cycle 4 (n=9)8.89 ± 18.33
Change in UOS at monotherapy Cycle 4 (n=9)2.78 ± 23.20
Change in EIP at monotherapy Cycle 4 (n=9)2.78 ± 23.20
Other pre-specifiedNumber of Participants Who Died While on Treatment and Died During 30-Day Post-Treatment Discontinuation Follow-Up (FU)

Presented are the number of participants who died due to adverse events (AEs) while on treatment and participants who died due to progressive disease (PD) during the 30-day post-treatment discontinuation FU.

Time frame:
From enrollment to 30 days post-treatment discontinuation up to 26.4 months
Reported as:
Number · participants
Number of Participants Who Died While on Treatment and Died During 30-Day Post-Treatment Discontinuation Follow-Up (FU)
participantsCetuximab + Pemetrexed + Carboplatin/Cisplatin
Due to AE while on treatment3
Due to PD during 30-day FU5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab + Pemetrexed + Carboplatin—23/63 (36.5%)63/63 (100%)
Cetuximab + Pemetrexed + Cisplatin—3/6 (50%)6/6 (100%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventCetuximab + Pemetrexed + CarboplatinCetuximab + Pemetrexed + Cisplatin
Myocardial infarctionCardiac disorders1/631/6
VomitingGastrointestinal disorders1/631/6
CachexiaMetabolism and nutrition disorders0/631/6
DehydrationMetabolism and nutrition disorders2/631/6
Febrile neutropeniaBlood and lymphatic system disorders4/630/6
DyspnoeaRespiratory, thoracic and mediastinal disorders4/630/6
Urinary tract infectionInfections and infestations3/630/6
Respiratory failureRespiratory, thoracic and mediastinal disorders3/630/6
AnaemiaBlood and lymphatic system disorders2/630/6
ThrombocytopeniaBlood and lymphatic system disorders2/630/6
Most frequent other events
Showing 10 of 107
Most frequent other events
EventCetuximab + Pemetrexed + CarboplatinCetuximab + Pemetrexed + Cisplatin
NauseaGastrointestinal disorders24/635/6
FatigueGeneral disorders44/635/6
VomitingGastrointestinal disorders10/634/6
DehydrationMetabolism and nutrition disorders13/634/6
Dermatitis acneiformSkin and subcutaneous tissue disorders21/634/6
AnaemiaBlood and lymphatic system disorders40/631/6
ThrombocytopeniaBlood and lymphatic system disorders31/633/6
DiarrhoeaGastrointestinal disorders17/633/6
DyspepsiaGastrointestinal disorders1/633/6
Mucosal inflammationGeneral disorders22/633/6

Baseline characteristics

All enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cetuximab + Pemetrexed + Carboplatin/Cisplatin
Mean61.9 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab + Pemetrexed + Carboplatin/Cisplatin
Female12
Male57
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cetuximab + Pemetrexed + Carboplatin/Cisplatin
Hispanic or Latino5
Not Hispanic or Latino63
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cetuximab + Pemetrexed + Carboplatin/Cisplatin
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American11
White56
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Cetuximab + Pemetrexed + Carboplatin/Cisplatin
United States69
European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)
European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)(units on a scale)Cetuximab + Pemetrexed + Carboplatin/Cisplatin
Index Score (n=47)0.721 ± 0.248
Visual Analog Scale (VAS) Score (n=47)66.106 ± 20.658
Performance Status Scale for Head and Neck Cancer (PSS-HNC)
Performance Status Scale for Head and Neck Cancer (PSS-HNC)(units on a scale)Cetuximab + Pemetrexed + Carboplatin/Cisplatin
NOD (n=57)56.32 ± 37.87
UOS (n=57)78.51 ± 32.20
EIP (n=57)71.93 ± 34.42
08

Study locations

21 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jonesboro, Arkansas 72401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Waterbury, Connecticut 06708, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Myers, Florida 33916, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32806, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marietta, Georgia 30060, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Savannah, Georgia 31405, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valdosta, Georgia 31602, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Scarborough, Maine 04074, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Detroit, Michigan 48202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis Park, Minnesota 55426, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Billings, Montana 59102, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bronx, New York 10467, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buffalo, New York 14263, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cincinnati, Ohio 45242, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbia, South Carolina 29210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sioux Falls, South Dakota 57104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chattanooga, Tennessee 37404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38119, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37203, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond, Virginia 23230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98109, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2010
First posted
Mar 16, 2010
Start
Aug 2010
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
May 19, 2014
Last update
May 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01087970
Responsible party
Sponsor
First posted
Mar 16, 2010
Start date
Aug 2010
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
May 19, 2014
Last update
May 19, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cetuximab · Carboplatin · Cisplatin

Start the discussion